Leaflet: information for the user
Bilina 0.5 mg/ml eye drops in suspension
Levocabastina
Read this leaflet carefully before starting to use this medication, as it contains important information for you.
Contents of the leaflet
Bilina 0.5 mg/ml eye drops in suspension contain levocabastina, which is an antihistamine used for the symptomatic treatment of allergic conjunctivitis in adults and in children and adolescents from 4 to less than 18 years of age.
Levocabastina is a highly selective antagonist of histamine H1 receptors. After application to the eyes, it provides rapid and long-lasting relief from the symptoms of allergic conjunctivitis (itching, redness, eyelid inflammation, tearing).
Do not use Bilina
Warnings and precautions
Consult your doctor or pharmacist before starting to use Bilina.
Children and adolescents
Using Bilina with other medications
No interactions have been described.
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medication.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you might be pregnant, or plan to become pregnant, do not use Bilina, as safety studies have not been conducted in pregnant women, and Bilina passes into breast milk. Consult your doctor or pharmacist before using this medication.
Driving and using machines
Bilina does not cause sedation or interfere with psychomotor activity. Adverse reactions with Bilina eye drops, such as eye irritation, pain, swelling, itching, redness, burning sensation, tearing, or blurred vision, have been reported, which may affect vision. Therefore, caution is recommended when driving or operating machinery after applying Bilina eye drops.
Bilina eye drops contain benzalkonium chloride
This medication contains 15 mg of benzalkonium chloride per ml.
Benzalkonium chloride can be absorbed by soft contact lenses, altering their color. Remove contact lenses before using this medication and wait 15 minutes before putting them back in.
Benzalkonium chloride can cause eye irritation, especially if you have dry eye or other corneal diseases (the transparent layer on the front of the eye). Consult your doctor if you feel any unusual sensation, itching, or pain in the eye after using this medication.
This medication contains 14.04 mg of phosphates per ml.
If you have severe corneal damage (the transparent layer on the front of the eye), treatment with phosphates, in very rare cases, may cause blurred vision due to calcium accumulation.
Follow your doctor's instructions for administering this medication exactly. If you have any doubts, consult your doctor or pharmacist again.
Adults and children and adolescents from 4 to less than 18 years of age
The recommended dose is 1 drop of Bilina per eye, 2 times a day. The dose can be increased to 1 drop in each eye, 3 or 4 times a day. Treatment should continue until symptoms disappear.
Use in children under 4 years of age
The safety and efficacy of this medication have not been established. No data are available.
Elderly
No data are available on the use of levocabastina in the elderly.
Before the first use of Bilina, remove the seal from the container and note the opening date on the box.
Follow these steps:
Do not touch the bottle to the eye to avoid introducing impurities into the remaining liquid. Do not use the drops for more than 1 month after opening the bottle for the first time.
Treatment should continue until symptoms improve.
If you use more Bilina than you should
If you accidentally drink the contents of a container, you may feel drowsy. In this case, it is recommended to drink plenty of non-alcoholic liquids to accelerate the elimination of the medication through the kidneys and contact your doctor immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to use Bilina
Do not apply an extra drop to the eye to make up for the missed dose.
If you have any other doubts about using this product, ask your doctor or pharmacist.
Like all medications, Bilina can cause side effects, although not everyone will experience them.
The frequency of the possible side effects listed below is defined using the following convention:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Frequency not known (cannot be estimated from the available data)
The side effects observed with Bilina are:
Common side effects (affecting between 1 and 10 in 100 patients) may include:
Very rare side effects (affecting less than 1 in 10,000 patients) may include:
If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet.
Reporting side effects:
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that is not listed in this leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep out of sight and reach of children.
Do not use this medication after the expiration date stated on the container after CAD. The expiration date is the last day of the month indicated.
Discard 28 days after the first opening of the container.
Do not store above 25°C.
Medications should not be disposed of through wastewater or household waste. Deposit the containers and medications you no longer need at the pharmacy's SIGRE point. If you have any doubts, ask your pharmacist how to dispose of the containers and medications you no longer need. This will help protect the environment.
Composition of Bilina
Appearance of the product and package contents
Bilina is presented as a sterile eye drop suspension, white in color, in a 4 ml plastic dropper bottle.
Marketing authorization holder and manufacturer
Marketing authorization holder
Esteve Pharmaceuticals, S.A.
Passeig de la Zona Franca, 109
08038 Barcelona
Spain
Manufacturer
Famar, S.A.
Agiou Dimitriou 63
Alimos Attiki
17456 Greece
Date of the last revision of this leaflet: September 2020
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
The average price of BILINA 0.5 mg/ml EYE DROPS IN SUSPENSION in October, 2025 is around 7.73 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.